Medical device manufacturers facing ethylene oxide (EtO) regulatory pressure can evaluate alternatives by working through four decision points: residual chemistry, established validation pathways, material and packaging compatibility, and current regulatory status. No single method replaces EtO across all device categories, and the US Environmental Protection Agency (EPA) states that identifying alternatives may take decades because innovations remain in early stages [2]. Rather than seeking a universal answer, a research team should use a documented example to make evaluation decisions concrete. Chlorine dioxide (ClO2) sterilization is useful for this purpose because recent literature proposes residual testing criteria and because FDA and EPA documents list it among sterilization methods, while CDC states that no gaseous chlorine dioxide system is FDA cleared [1][2][3][5]. A structured evaluation can still identify specific candidate modalities and show where evidence ends.
Why EtO Creates a Distinct Evaluation Problem
EtO remains central to US medical device sterilization partly because it is a penetrative gas with long-established validation standards. EPA notes that absence of EtO would disrupt availability of feeding tubes used in neonatal intensive care units, drug-eluting cardiac stents, catheters, shunts, and other implantable devices [2]. The agency also states that some devices can only be sterilized with EtO, while other devices can use gamma irradiation, X-ray, electron beam, steam, or methods in development such as vaporized hydrogen peroxide, nitrogen dioxide, chlorine dioxide, and vaporized peracetic acid [2]. The persistence of EtO is therefore not a single technical barrier but a combination of supply-chain scale, capacity, and validation history.
FDA guidance reinforces this point by distinguishing established methods from newer ones. FDA describes dry heat, EtO, steam, radiation, and vaporized hydrogen peroxide as established methods with a long history of safe and effective use and recognized consensus standards for development, validation, and routine control [4]. Other methods may lack that accumulated documentation. Manufacturers evaluating alternatives should ask whether a candidate method has a recognized standard, a pilot program, or only published exploratory data. The answer determines how much of the regulatory burden the manufacturer would carry and how much historical evidence can be borrowed from prior clearances.
Residual Chemistry as the First Screen
EtO is a known carcinogen that leaves carcinogenic residuals, which is a key reason regulatory changes encourage manufacturers to consider non-carcinogenic sterilants [1]. A candidate method should therefore be screened first by residual species and the availability of acceptance criteria. For chlorine dioxide, researchers at Baron Analytical Laboratories used ion chromatography to detect chloride, chlorite, and chlorate residuals down to parts per million [1]. They developed acceptance criteria using long-term oral consumption no-adverse-effect levels (NOAELs) and drew on US Environmental Protection Agency and World Health Organization drinking water guidelines [1].
The study analyzed devices including one indicated for incidental contact, a device to treat corneal abrasions, a smoking cessation inhaler, a device to treat embolisms, polychlorotrifluoroethylene bottles, and prefilled syringes [1]. Reported residual levels were below toxicity limits of less than 6.83 mg per device or less than 0.8 mg/L for chlorite and less than 70.65 mg per device or less than 0.7 mg/L for chlorate, and the authors reported no toxic residuals after application [1]. However, the authors also note that future research must include high-contact devices such as implantable devices designed for long-term use [1]. One device result was considered inconclusive because instrument sensitivity levels were set insufficiently low [1]. These limits show that a residual screen is only as strong as the method detection design and the device contact categories it includes.
A Suggested Hypothetical Evaluation Layout
A research team could use the following suggested layout without implying that any testing has been performed. First, define the device contact category and packaging. Second, list candidate methods from FDA and EPA documents and mark each as established, in development, or described in published studies [2][3][4]. Third, create a residuals column specifying species and acceptance criteria where available; for chlorine dioxide, record the chlorite and chlorate limits reported in the 2025 study and note the absence of high-contact device data [1].
Fourth, create a compatibility and penetration column using documented cautions such as cellulose and nylon limitations for vaporized hydrogen peroxide and the lower penetration than EtO reported by CDC [5]. Fifth, create a validation column that identifies whether a recognized standard exists; EtO has two named standards, while some new methods do not [3]. This layout would show which decision points are supported by current documents and which require new testing, but it should be labeled as a planning tool rather than a validated comparison.
Comparing Candidate Modalities on Decision Points
After residual screening, a manufacturer should compare candidate methods against compatibility, penetration, scalability, and validation status. EPA states that alternative methods face limitations in material and packaging compatibility, scalability or capacity, application method, and lack of standardized validation measures for sterility assurance or efficacy data [2]. The agency also states that capacity for alternatives is not sufficient to begin replacing EtO at scale and that alternatives are being identified on a product-by-product basis [2]. These statements mean that a comparison should be documented per device family rather than assumed across a portfolio.
Public health sources provide specific compatibility cautions. CDC describes vaporized hydrogen peroxide as having rapid cycle time of roughly 30 to 45 minutes, low temperature, and environmentally safe by-products of water and oxygen, but notes that cellulose cannot be processed, nylon becomes brittle, and penetration capabilities are less than those of EtO [5]. CDC also states that no gaseous chlorine dioxide system is FDA cleared [5]. For chlorine dioxide, CDC cites a research example in which 40 mg/L required 30 minutes to sterilize 10^6 B. atrophaeus spores at 30 to 32 degrees Celsius [5]. These documented limitations should be recorded as conditional constraints, not as reasons to eliminate a method.
Regulatory Pathways and Pilot Programs as Evidence Sources
FDA has created pilot programs that can reveal how specific providers are positioning alternative or modified methods, although participation does not establish that a method is cleared for a given device. The Radiation Sterilization Master File Pilot Program for PMA holders includes Steris Corporation with an acceptance date of October 27, 2023, and the EtO Sterility Change Master File Pilot Program includes Andersen Scientific, Inc. with an acceptance date of June 28, 2023 [3][6]. The radiation pilot is limited to single-use PMA-approved devices and does not include 510(k)-cleared devices [6]. These named participants show where regulatory experimentation is occurring, but they do not provide efficacy data for a new modality.
Manufacturers evaluating a method should also check whether FDA describes it as established. FDA guidance lists dry heat, EO, steam, radiation, and vaporized hydrogen peroxide as Established Category A methods with recognized consensus standards [4]. FDA has also stated that it now considers vaporized hydrogen peroxide, ozone, and flexible bag systems to be established methods [4]. A manufacturer that selects a method outside this list may need to generate more validation evidence. For EtO specifically, ANSI AAMI ISO 11135:2014 and ANSI AAMI ISO 10993-7:2008(R)2012 describe process development, validation, and residual limits [3]. The absence of an equivalent standard for a candidate method should be treated as a known evidence gap.
What the Current Evidence Cannot Establish
Several unknowns limit any alternative evaluation. EPA states that there are currently no available alternatives, pesticidal or non-pesticidal, for some devices because of challenges such as material compatibility, scalability, and capacity [2]. AORN guidance explicitly excludes sterilization processes not cleared by FDA for use in health care facilities, including gamma or electron beam radiation, chlorine dioxide, nitrogen dioxide, and formaldehyde, as well as industrial EO sterilization [7]. CDC similarly lists vaporized hydrogen peroxide, vapor phase peracetic acid, gaseous chlorine dioxide, ionizing radiation, and pulsed light as technologies under development but not cleared by FDA for healthcare facilities, and states there is no guarantee they will receive clearance [8].
The chlorine dioxide residual study itself illustrates the gap between laboratory findings and clinical or regulatory readiness. The authors conclude that ClO2 sterilization is an effective, certified alternative to EtO and that results support adoption for medical devices with limited patient contact, while calling for future research on high-contact and long-term implantable devices [1]. CDC separately states that chlorine dioxide is not mutagenic or carcinogenic in humans but also states that no gaseous chlorine dioxide system is FDA cleared [5]. These two statements are not in conflict, but they mean a manufacturer cannot treat published residual data as equivalent to regulatory clearance for a specific device or cycle.
Sources & references
- Chlorine Dioxide Medical Device Sterilization: Residual Toxicity Testing | Journal of Medical and Biological Engineering | Springer Nature Link · link.springer.com
- US EPA - Ethylene Oxide - Interim Registration Review Decision - Case Number 2275 · www.epa.gov
- Sterilization for Medical Devices | FDA · www.fda.gov
- Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile · www.fda.gov
- Other Sterilization Methods | Infection Control | CDC · www.cdc.gov
- Sterilization for Medical Devices | FDA · www.fda.gov
- Sterilization | AORN eGuidelines+ · www.aornguidelines.org
- Low-Temperature Sterilization Technologies | Infection Control | CDC · www.cdc.gov